Tag Archives: Sanofi Pasteur

Articles of Interest

Bird Flu Vaccine? World Experts Debate Whether To Make Shot For New H7N9 Strain

Leave a comment

By The Huffington Post News Editors

* Experts in daily talks on risks posed by new China virus
* Researchers analysing samples to find vaccine candidate
* Decision to make vaccine depends on whether H7N9 spreads
By Ben Hirschler and Kate Kelland
LONDON, April 4 (Reuters) – Experts from around the world are in daily talks about the threat posed by a deadly new strain of bird flu in China, including discussions on if and when to start making a vaccine.
Any decision to mass-produce vaccines against H7N9 flu will not be taken lightly, since it will mean sacrificing production of seasonal shots. And scientists warn it will take months to get any finished bird flu vaccine to the market.
But the groundwork is being laid.
The virus has been shared with World Health Organization (WHO) collaborating centres in Atlanta, Beijing, London, Melbourne and Tokyo, and these groups are analysing samples to identify the best candidate to be used for the manufacture of vaccine – if it becomes necessary.
It is still a big “if”, even assuming the continued spread of the new disease, which has killed five of the 14 people that it has infected in China.
“It is an incredibly difficult decision because once you make it you have to change from making seasonal flu vaccines and go to making a vaccine for this virus,” said Jeremy Farrar, a leading expert on infectious diseases and director of Oxford University’s research unit in Vietnam.
That could mean shortages of vaccine against the normal seasonal flu which, while not serious for most people, still costs thousands of lives.
Sanofi Pasteur, the world’s largest flu vaccine manufacturer, said it was in continuous contact with the WHO through the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), but it was too soon to know the significance of the Chinese cases. …read more

Source: FULL ARTICLE at Huffington Post

Business, Finance, Occupation & Industry

Jacobs Receives Contract from Sanofi Pasteur for Aguila II Project

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Jacobs Receives Contract from Sanofi Pasteur for Aguila II Project

PASADENA, Calif.–(BUSINESS WIRE)– Jacobs Engineering Group Inc. (NYS: JEC) announced today that it was awarded a contract from Sanofi Pasteur to provide detail engineering services for the expansion and refurbishment of its Flu Vaccine Facility in Ocoyoacac, Mexico.

Officials did not disclose the contract value, but noted that this is the second phase of the Aguila Project; the first phase was executed in 2010 by Jacobs’ offices in Lyon, France and Mexico City, Mexico. Jacobs is executing this detail engineering phase of the project from its Mexico operations. The overall goal of the project is to increase plant production capacity.

In making the announcement, Jacobs Group Vice President Mike Autrey stated, “We are committed to a long term relationship with Sanofi and we are very pleased to be part of this plant production expansion project. We look forward to continuing to deliver value and technical excellence to Sanofi.”

Jacobs is one of the world’s largest and most diverse providers of technical, professional, and construction services.

Statements made in this release that are not based on historical fact are forward-looking statements. We base these forward-looking statements on management’s current estimates and expectations as well as currently available competitive, financial and economic data. Forward-looking statements, however, are inherently uncertain. There are a variety of factors that could cause business results to differ materially from our forward-looking statements. For a description of some of the factors which may occur that could cause actual results to differ from our forward-looking statements please refer to our 2012 Form 10-K, and in particular the discussions contained under Items 1 – Business, 1A – Risk Factors, 3 – Legal Proceedings, and 7 – Management’s Discussion and Analysis of Financial Condition and Results of Operations. We do not undertake to update any forward-looking statements made herein.

Jacobs Engineering Group Inc.
Michelle Jones, 626.578.6968

KEYWORDS:   United States  Mexico  North America  Central America  California

INDUSTRY KEYWORDS:

The article Jacobs Receives Contract from Sanofi Pasteur for Aguila II Project originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Sanofi and Transgene Announce Innovative Long-Term Collaboration for the Production of Immunotherapy

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Sanofi and Transgene Announce Innovative Long-Term Collaboration for the Production of Immunotherapy Treatments


– Creation of a new state-of-the-art industrial platform at Genzyme’s unit in Lyon –

PARIS & STRASBOURG, France–(BUSINESS WIRE)– Regulatory News:

Sanofi (EURONEXT: SAN and NYSE: SNY) and Transgene SA (Paris:TNG) (NYSE-Euronext: TNG) announced today a collaboration agreement for the creation of a new state-of-the-art industrial platform dedicated to the production of immunotherapy products including Transgene’s therapeutic products. The platform will be realized on Genzyme Polyclonals site in Lyon – Gerland area for an investment amount of 10 million euro equally financed by Sanofi and Transgene. The Platform will remain Sanofi’s exclusive property.

Sanofi and Genzyme will act as Transgene’s Contract Manufacturing Organization (CMO) to manufacture clinical and commercial batches of drug substance of Transgene’s immunotherapy products, including its MVA1 therapeutic vaccines. Transgene will be a preferred customer of the commercial manufacturing platform for 15 years.

“Transgene is extremely pleased to announce this agreement with the Sanofi Group, as it combines the strong expertise of recognized experts and pioneers in the fields of gene therapy and vaccines,” said Philippe Archinard, Chairman and Chief Executive Officer of Transgene. “This collaboration will secure Transgene’s commercial production over the long run, enabling us to focus our resources on development and marketing of our products.“

“TheLyon area is a strategic place for Sanofi in the field of immunology, and I am extremely pleased to announce this collaboration with Transgene, representing a total investment of 10 million euro on Genzyme Polyclonals site in the Lyon Gerland area,” said Olivier Charmeil, President and CEO of Sanofi Pasteur. “Merial, Sanofi Pasteur and Genzyme will share locally their expertise to successfully implement this state-of-the-art platform and build a center of excellence available for Transgene and potentially other customers.”

“The agreement between Transgene and Sanofi is symbolic at more than one level”, said Alain Mérieux, Chairman of Institut Mérieux. “It brings into play operational synergies between the pharmaceutical and biotechnology industries in a place of historical importance for Institut Mérieux. The agreement also reinforces the ecosystem in Lyon, where we and other industry players have learned to work together within the context of the local cluster (Lyon Biopole) and of the newly created Research Technology Institute (Bioaster).“

Genzyme Polyclonals site in Lyon – Gerland area – …read more
Source: FULL ARTICLE at DailyFinance